4A10, a monoclonal antibody targeting interleukin-7 receptor alpha (IL-7Rα; CD127), has received fast track designation from the FDA for the treatment of patients with relapsed or refractory acute ...
Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...
FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of ...
Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
Ziftomenib is the first Menin inhibitor approved for relapsed or refractory mutant nucleophosmin 1 acute myeloid leukemia, showing promising efficacy in clinical trials. The phase 2 KOMET-001 trial ...
In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies. The FDA has approved the OncoMate® MSI Dx ...
The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback